Table 3:

New pharmacologic therapies for acute treatment of migraine, with or without aura

Drug	Ubrogepant	Rimegepant*	Lasmiditan†
Mechanism of action	CGRP receptor antagonist	CGRP receptor antagonist	5-HT1F receptor agonist
Dosing	Oral: 50 or 100 mg as needed (max 2 doses/24 h)	Oral or sublingual: 75 mg as needed (max 1 dose/24 h)	Oral; 50, 100 or 200 mg as needed (max 1 dose/24 h)
Adverse effects	Nausea, dizziness and dry mouth	Nausea and abdominal pain and dyspepsia	Dizziness, drowsiness, paresthesia, nausea, vomiting and muscle weakness

Note: CGRP = calcitonin gene-related peptide.

^*Rimegepant is not yet approved in Canada.

^†Lasmiditan is not expected to be coming to the Canadian market at the present time. Label warning: avoid driving within 8 hours of its use.